In a phase 2 trial, a regimen of gemcitabine plus eribulin compared favorably with other regimens for the first-line treatment of cisplatin-ineligible patients with metastatic urothelial carcinoma.
Patients who undergo surgical resection of nonmetastatic upper tract urothelial carcinoma with isolated lymph node involvement have a 5-year overall survival rate of only 24%, a study found.
Female sex, prior urinary tract infection, and longer operative time are associated with increased odds of UTI following flexible ureteroscopy, a study found.
In a single-center study of patients with asymptomatic microscopic hematuria, renal ultrasonography demonstrated 100% sensitivity for detecting upper tract urothelial carcinoma and renal cell carcinoma.
In a study of patients with upper tract urothelial carcinoma, Asians were 27% more likely than whites to die from the disease.
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
The investigators said the data justify and support the submission of enfortumab vedotin for consideration under FDA’s accelerated approval pathway.
Longer follow-up of patients in the KEYNOTE-052 trial confirms the anti-tumor effect of first-line pembrolizumab in patients with cisplatin-ineligible advanced urothelial carcinoma.
The median duration of complete response to atezolizumab in patients with locally advanced or metastatic urothelial carcinoma is more than 2 years, new data suggest.
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
